Adenoma, Islet Cell - 25 Studies Found
| Not yet recruiting |
: Phase II Study to Evaluate Efficacy of Rechallenge With Sunitinib in Patients With Metastatic Pancreatic Neuroendocrine Tumor (pNETs) Who Previously Failed to Sunitinib : Pancreatic Neuroendocrine Tumour Metastatic : 2016-03-16 : Drug: Sunitinib Sunitinib 37.5 mg/day |
| Not yet recruiting |
: Pancreatic Neuroendocrine Tumor：Factor of Surgery Influencing Survival : Pancreatic Neuroendocrine Tumor : 2015-11-30 : Procedure: pancreatectomy Remove the pancreatic neuroendocrine tumor by surgery |
| Recruiting |
: Phase III Study of Sulfatinib in Treating Advanced Pancreatic Neuroendocrine Tumors : Neuroendocrine Tumors : 2015-10-26 :
|
| Recruiting |
: Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors :
: 2015-10-12 : Drug: Ibrutinib Ibrutinib will be administered orally once daily and each cycle will be defined as 4 wee |
| Recruiting |
: Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors : Neuroendocrine Tumors : 2015-06-16 :
|
| Completed |
: An Analysis of Presentation and Outcome Following Treatment of Pancreatic Endocrine Neoplasms : Pancreatic Endocrine Neoplasms : 2015-03-23 |
| Recruiting |
: A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus : Pancreatic Neuroendocrine Tumour Metastatic : 2014-06-17 : Drug: Everolimus 10 mg daily everolimus is a recently approved mTOR inhibitor in advanced progressing we |
| Recruiting |
: A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET) : Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours : 2014-09-23 :
|
| Recruiting |
: The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors : Pancreatic Neuroendocrine Tumors : 2014-10-15 : Drug: sunitinib subjects will be enrolled to receive at least one dose of sunitinib orally at 37.5 mg on |
| Recruiting |
: Observational Study In Real Life Settings Of The Systemic Treatment Of Well Differentiated, Unresectable Or Metastatic, Progressive Pancreatic Neuroendocrine Tumors (pNET): A Study Of Morbidity And Mortality At 2 Years : Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive : 2014-09-02 :
|